The Filings Report

Corcept Therapeutics Inc.

CORTNasdaqCIK 1088856Healthcare / Drug Manufacturersfiscal year ends December66 quarters since 2010

Revenue, Q3 FY2026
$340M
+64.0% on Q3 FY2025
Net income
$127M
+544.6% on Q3 FY2025
Free cash flow
$142M
+161.0% on Q3 FY2025
Diluted EPS
$1.01
+531.3% on Q3 FY2025
Revenue, TTM
$964M
trailing four quarters
Net margin, TTM
16.8%
net income $162M
Free cash flow, TTM
$195M
$198M less $3M capex
Cash and equivalents
$99M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+4.0%
109M shares, Sep 30, 2026
Buybacks, TTM
$6M
0.1% of market value
Dividends, TTM
—
no yield
Market value
$8.8B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Corcept Therapeutics Inc. reported revenue of $340M, +64.0% on Q3 FY2025, and net income of $127M (+544.6%). Operating margin was 33.7%. Free cash flow, operating cash flow less capital expenditures, was $142M ($143M less $709K). Diluted earnings per share were $1.01.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 3, 2026.

Revenue and net incomeRevenueNet income
−$100M$0$100M$200M$300M$400MQ4'22, Revenue: $103MQ4'22, Net income: $17MQ4'22Q1'23, Revenue: $106MQ1'23, Net income: $16MQ1'23Q2'23, Revenue: $118MQ2'23, Net income: $28MQ2'23Q3'23, Revenue: $124MQ3'23, Net income: $31MQ3'23Q4'23, Revenue: $135MQ4'23, Net income: $31MQ4'23Q1'24, Revenue: $147MQ1'24, Net income: $28MQ1'24Q2'24, Revenue: $164MQ2'24, Net income: $35MQ2'24Q3'24, Revenue: $183MQ3'24, Net income: $47MQ3'24Q4'24, Revenue: $182MQ4'24, Net income: $31MQ4'24Q1'25, Revenue: $157MQ1'25, Net income: $21MQ1'25Q2'25, Revenue: $194MQ2'25, Net income: $35MQ2'25Q3'25, Revenue: $208MQ3'25, Net income: $20MQ3'25Q4'25, Revenue: $202MQ4'25, Net income: $24MQ4'25Q1'26, Revenue: $165MQ1'26, Net income: −$32MQ1'26Q2'26, Revenue: $256MQ2'26, Net income: $43MQ2'26Q3'26, Revenue: $340MQ3'26, Net income: $127MQ3'26−$100M$0$100M$200M$300M$400MQ4'22, Revenue: $103MQ4'22, Net income: $17MQ1'23, Revenue: $106MQ1'23, Net income: $16MQ1'23Q2'23, Revenue: $118MQ2'23, Net income: $28MQ3'23, Revenue: $124MQ3'23, Net income: $31MQ3'23Q4'23, Revenue: $135MQ4'23, Net income: $31MQ1'24, Revenue: $147MQ1'24, Net income: $28MQ1'24Q2'24, Revenue: $164MQ2'24, Net income: $35MQ3'24, Revenue: $183MQ3'24, Net income: $47MQ3'24Q4'24, Revenue: $182MQ4'24, Net income: $31MQ1'25, Revenue: $157MQ1'25, Net income: $21MQ1'25Q2'25, Revenue: $194MQ2'25, Net income: $35MQ3'25, Revenue: $208MQ3'25, Net income: $20MQ3'25Q4'25, Revenue: $202MQ4'25, Net income: $24MQ1'26, Revenue: $165MQ1'26, Net income: −$32MQ1'26Q2'26, Revenue: $256MQ2'26, Net income: $43MQ3'26, Revenue: $340MQ3'26, Net income: $127MQ3'26

Net income losses drawn in red.

Free cash flow
−$50M$0$50M$100M$150MQ4'22, Free cash flow: $33MQ4'22Q1'23, Free cash flow: $26MQ1'23Q2'23, Free cash flow: $42MQ2'23Q3'23, Free cash flow: $53MQ3'23Q4'23, Free cash flow: $6MQ4'23Q1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $41MQ2'24Q3'24, Free cash flow: $72MQ3'24Q4'24, Free cash flow: $60MQ4'24Q1'25, Free cash flow: $5MQ1'25Q2'25, Free cash flow: $44MQ2'25Q3'25, Free cash flow: $54MQ3'25Q4'25, Free cash flow: $38MQ4'25Q1'26, Free cash flow: −$17MQ1'26Q2'26, Free cash flow: $31MQ2'26Q3'26, Free cash flow: $142MQ3'26−$50M$0$50M$100M$150MQ4'22, Free cash flow: $33MQ1'23, Free cash flow: $26MQ1'23Q2'23, Free cash flow: $42MQ3'23, Free cash flow: $53MQ3'23Q4'23, Free cash flow: $6MQ1'24, Free cash flow: $24MQ1'24Q2'24, Free cash flow: $41MQ3'24, Free cash flow: $72MQ3'24Q4'24, Free cash flow: $60MQ1'25, Free cash flow: $5MQ1'25Q2'25, Free cash flow: $44MQ3'25, Free cash flow: $54MQ3'25Q4'25, Free cash flow: $38MQ1'26, Free cash flow: −$17MQ1'26Q2'26, Free cash flow: $31MQ3'26, Free cash flow: $142MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$100M$200M$300MQ4'22, Cash and equivalents: $66MQ4'22Q1'23, Cash and equivalents: $300MQ1'23Q2'23, Cash and equivalents: $172MQ2'23Q3'23, Cash and equivalents: $112MQ3'23Q4'23, Cash and equivalents: $136MQ4'23Q1'24, Cash and equivalents: $150MQ1'24Q2'24, Cash and equivalents: $129MQ2'24Q3'24, Cash and equivalents: $137MQ3'24Q4'24, Cash and equivalents: $128MQ4'24Q1'25, Cash and equivalents: $90MQ1'25Q2'25, Cash and equivalents: $103MQ2'25Q3'25, Cash and equivalents: $125MQ3'25Q4'25, Cash and equivalents: $120MQ4'25Q1'26, Cash and equivalents: $109MQ1'26Q2'26, Cash and equivalents: $111MQ2'26Q3'26, Cash and equivalents: $99MQ3'26$0$100M$200M$300MQ4'22, Cash and equivalents: $66MQ1'23, Cash and equivalents: $300MQ1'23Q2'23, Cash and equivalents: $172MQ3'23, Cash and equivalents: $112MQ3'23Q4'23, Cash and equivalents: $136MQ1'24, Cash and equivalents: $150MQ1'24Q2'24, Cash and equivalents: $129MQ3'24, Cash and equivalents: $137MQ3'24Q4'24, Cash and equivalents: $128MQ1'25, Cash and equivalents: $90MQ1'25Q2'25, Cash and equivalents: $103MQ3'25, Cash and equivalents: $125MQ3'25Q4'25, Cash and equivalents: $120MQ1'26, Cash and equivalents: $109MQ1'26Q2'26, Cash and equivalents: $111MQ3'26, Cash and equivalents: $99MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Corcept Therapeutics Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue340256165202208194157182+64.0%
Cost of revenue54335323+0.3%
Gross profit—————————
Research and development5754666569606170−17.6%
Selling, general and administrative1641571451301241049183+32.6%
Operating income11541(50)41027325+1022.7%
Other income (expense)65555567+11.1%
Pretax income12046(45)1015321032+689.3%
Income tax(6)3(13)(14)(4)(3)(11)1−46.2%
Net income12743(32)2420352131+544.6%
Diluted EPS ($)1.010.36(0.30)—0.160.290.17—+531.3%
Diluted shares (millions)123118104—119120120——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Corcept Therapeutics Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents9911110912012510390128−21.1%
Short-term investments272197229252297239233256−8.3%
Total current assets534440426485541443439472−1.3%
Total assets1,034889815837824802846841+25.5%
Total current liabilities178154149166172145143141+3.1%
Long-term debt—————————
Total liabilities200183177189192166163161+4.5%
Stockholders’ equity834706638648632636683680+31.9%
Shares outstanding (millions)109108107106105105106106—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

Corcept Therapeutics Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 24, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow14334(17)385444560+162.3%
Capital expenditures13000000—
Free cash flow (CFO − capex)14231(17)385444560+161.0%
Depreciation and amortization11100000+115.1%
Share repurchases600042103270−86.5%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 24, 2026.

Income statement

Corcept Therapeutics Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 10, 2016FY2014ended Dec 31, 2014filed Mar 13, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 9, 2011FY2009ended Dec 31, 2009filed Aug 9, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012
Revenue761675482402366354306251159815027103——0—————————
Cost of revenue1311655665421100————————————
Gross profit——————————————————————————
Research and development2552471841311141158975402415182014211914—————————
Selling, general and administrative449280184153122105100816245373531251186—————————
Operating income45137107113124128112895310(3)(28)(41)(36)(32)(27)(20)—————————
Other income (expense)22251741—————————————————————
Pretax income6616112511612513211792538(6)———————————————
Income tax(33)20181512262217(76)000——————————————
Net income10014110610111310694751298(6)(31)(46)(38)(32)(26)(20)(20)(12)(25)(20)(16)(10)(19)(7)(2)
Diluted EPS ($)0.821.230.940.870.890.850.770.601.040.07(0.06)———————————————
Diluted shares (millions)120113112116126124123127125116107101——————————————

Balance sheet

Corcept Therapeutics Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 10, 2016FY2014ended Dec 31, 2014filed Mar 13, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 9, 2011FY2009ended Dec 31, 2009filed Aug 9, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012
Cash and equivalents120128136667876314231524024559340252415————————
Short-term investments252256233365146365245165580————————————————
Total current assets48547245949926647930723712466493058954025——————————
Total assets83784162258342457241231222169523563994025——————————
Total current liabilities16614110572484739363027211413854——————————
Long-term debt————————0013242929————————————
Total liabilities189161115824848413630—————————————————
Stockholders’ equity6486805075023765233712761914118(3)2162352122171562746(31)(22)(8)(2)
Shares outstanding (millions)10610610410810611711511511511311010110110084———————————

Cash flow statement

Corcept Therapeutics Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 24, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 28, 2023FY2021ended Dec 31, 2021filed Feb 15, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 6, 2017FY2015ended Dec 31, 2015filed Mar 10, 2016FY2014ended Dec 31, 2014filed Mar 13, 2015FY2013ended Dec 31, 2013filed Mar 14, 2014FY2012ended Dec 31, 2012filed Mar 15, 2013FY2011ended Dec 31, 2011filed Mar 13, 2012FY2010ended Dec 31, 2010filed Aug 9, 2011FY2009ended Dec 31, 2009filed Aug 9, 2011FY2008ended Dec 31, 2008filed Mar 13, 2012FY2007ended Dec 31, 2007filed Mar 13, 2012FY2006ended Dec 31, 2006filed Mar 13, 2012FY2005ended Dec 31, 2005filed Mar 13, 2012FY2004ended Dec 31, 2004filed Mar 13, 2012FY2003ended Dec 31, 2003filed Mar 13, 2012FY2002ended Dec 31, 2002filed Mar 13, 2012FY2001ended Dec 31, 2001filed Mar 13, 2012FY2000ended Dec 31, 2000filed Mar 13, 2012
Operating cash flow1421981271201681521361166118——(37)(36)(27)(22)(18)—————————
Capital expenditures020001100000000———————————
Free cash flow (CFO − capex)1421961271201671511351156118——(37)(36)(27)———————————
Depreciation and amortization11111110000000000—————————
Share repurchases1731600—10312400————————————————
Dividends paid——————————————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 3, 2024 to November 3, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$42M
44 sales by 8 insiders; officers and directors $42M
Bought, twelve months
$3M
2 purchases by 1 insider; officers and directors $3M
Sold, twelve months
$102M
111 sales by 10 insiders; officers and directors $102M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect6,654$114.48$762K1MOct 16, 2026
Oct 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect3,046$115.39$351K1MOct 16, 2026
Oct 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect300$116.30$35K1MOct 16, 2026
Oct 2, 2026Vieira Roberto WandenkolkPresident, Oncologyoption exercise8,333$21.63$180K12,279Oct 5, 2026
Oct 2, 2026Vieira Roberto WandenkolkPresident, Oncologyopen-market sale10b5-11,100$114.52$126K11,179Oct 5, 2026
Oct 2, 2026Vieira Roberto WandenkolkPresident, Oncologyopen-market sale10b5-12,086$115.73$241K9,093Oct 5, 2026
Oct 2, 2026Vieira Roberto WandenkolkPresident, Oncologyopen-market sale10b5-15,147$116.58$600K3,946Oct 5, 2026
Oct 2, 2026Lyon Joseph DouglasSee Remarksoption exercise3,357$13.56$46K9,040Oct 5, 2026
Oct 2, 2026Lyon Joseph DouglasSee Remarksoption exercise5,833$19.26$112K14,873Oct 5, 2026
Oct 2, 2026Lyon Joseph DouglasSee Remarksopen-market sale10b5-14,446$115.70$514K10,427Oct 5, 2026
Oct 2, 2026Lyon Joseph DouglasSee Remarksopen-market sale10b5-14,744$116.54$553K5,683Oct 5, 2026
Oct 2, 2026Maduck SeanSee Remarksoption exercise24,587$8.27$203K34,525Oct 5, 2026
Oct 2, 2026Maduck SeanSee Remarksopen-market sale10b5-115,843$116.12$2M18,682Oct 5, 2026
Oct 2, 2026Maduck SeanSee Remarksopen-market sale10b5-18,744$116.55$1M9,938Oct 5, 2026
Oct 1, 2026Lyon Joseph DouglasSee Remarksoption exercise810$13.56$11K6,493Oct 5, 2026
Oct 1, 2026Lyon Joseph DouglasSee Remarksopen-market sale10b5-1810$115.40$93K5,683Oct 5, 2026
Oct 1, 2026Maduck SeanSee Remarksoption exercise413$8.27$3K10,351Oct 5, 2026
Oct 1, 2026Maduck SeanSee Remarksopen-market sale10b5-1413$115.54$48K9,938Oct 5, 2026
Sep 24, 2026Robb Gary CharlesChief Business Officergift17,100$0.00—14,056Sep 28, 2026
Sep 24, 2026Robb Gary CharlesChief Business Officergiftindirect5,000$0.00—20,571Sep 28, 2026
Sep 17, 2026Robb Gary CharlesChief Business Officeroption exercise17,493$8.27$145K31,156Sep 18, 2026
Sep 16, 2026Vieira Roberto WandenkolkPresident, Oncologyopen-market sale10b5-1296$100.82$30K3,946Sep 18, 2026
Sep 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect6,800$110.27$750K1MSep 16, 2026
Sep 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect400$110.84$44K1MSep 16, 2026
Sep 15, 2026Wilson James NDirectoropen-market sale10b5-1indirect2,800$111.70$313K1MSep 16, 2026

Full insider history for Corcept Therapeutics Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CORCEPT THERAPEUTICS INC, CIK 1088856 on EDGAR
Extract generated
November 4, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueGoodsNet, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 4, 2026.

JSON file
/data/financials/CORT.json